Troy Cox
Insider
First SEC filing: March 18, 2026 · Latest: March 18, 2026
Insider at
Insider transactions
1 buys (P)
0 sells (S)
Net: $148,702
Avg return of open purchases vs now: 3.2%
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 28, 2026 | MPLT | P | 15,620 | $9.52 | $148,702 | 15,620 Indirect | · | Acquired | 3.2% (price as of 2026-10-02) |
| June 23, 2026 | MPLT | A | 29,804 | · | · | 29,804 Direct | · | Acquired | (price as of 2026-10-02) |
| June 23, 2026 | MPLT | A | 7,864 | · | · | 7,864 Direct | · | Acquired | (price as of 2026-10-02) |
| June 18, 2026 | LAB | A | 175,923 | · | · | 175,923 Direct | · | Acquired | (price as of 2026-10-02) |
| June 18, 2026 | LAB | A | 99,116 | · | · | 475,702 Direct | +26.32% | Acquired | (price as of 2026-10-02) |
| June 18, 2026 | SOPH | A | 28,818 | $5.46 | $157,346 | 252,809 Direct | +12.87% | Acquired | 47.8% (price as of 2026-10-02) |
| June 18, 2026 | SOPH | A | 19,724 | $5.46 | $107,693 | 328,743 Direct | +6.38% | Acquired | 47.8% (price as of 2026-10-02) |
| Feb. 26, 2026 | LAB | A | 57,264 | $1.17 | $66,999 | 376,586 Direct | +17.93% | Acquired | -36.4% (price as of 2026-10-02) |
| June 20, 2025 | LAB | A | 125,660 | · | · | 125,660 Direct | · | Acquired | (price as of 2026-10-02) |
| June 20, 2025 | LAB | A | 94,592 | · | · | 256,412 Direct | +58.46% | Acquired | (price as of 2026-10-02) |
| Feb. 28, 2025 | LAB | A | 62,910 | $1.06 | $66,685 | 224,730 Direct | +38.88% | Acquired | -29.7% (price as of 2026-10-02) |
| Dec. 10, 2024 | ZYME | A | 31,000 | · | · | 31,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 28, 2024 | LAB | A | 72,213 | · | · | 72,213 Direct | · | Acquired | (price as of 2026-10-02) |
| June 28, 2024 | LAB | A | 43,128 | · | · | 161,820 Direct | +36.34% | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 184,999 | · | · | 184,999 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 190,365 | · | · | 190,365 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 982,811 | · | · | 982,811 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 22,866 | · | · | 22,866 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 51,842 | · | · | 51,842 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 31,635 | · | · | 198,104 Direct | +19.00% | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 79,412 | · | · | 166,469 Direct | +91.22% | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | LAB | A | 87,057 | · | · | 87,057 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 7, 2023 | ZYME | A | 37,000 | · | · | 37,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 21, 2022 | ZYME | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 23, 2026 | MPLT | Stock Option (right to buy) | Voting Common Stock | $28.64 | June 22, 2036 | 29,804 | Acquired |
| June 18, 2026 | LAB | Stock Option (Right to buy) | Common Stock | $0.83 | June 18, 2036 | 175,923 | Acquired |
| June 18, 2026 | SOPH | Share Option (Right to Buy) | Ordinary Shares | $5.46 | June 18, 2036 | 28,818 | Acquired |
| June 20, 2025 | LAB | Stock Option (Right to buy) | Common Stock | $1.05 | June 20, 2035 | 125,660 | Acquired |
| Dec. 10, 2024 | ZYME | Stock Option (Right to Buy) | Common Stock | $13.06 | Dec. 9, 2034 | 31,000 | Acquired |
| June 28, 2024 | LAB | Stock Option (Right to buy) | Common Stock | $1.77 | June 28, 2034 | 72,213 | Acquired |
| Jan. 5, 2024 | LAB | Warrant to purchase Common Stock (Right to buy) | Common Stock | $11.50 | Sept. 1, 2026 | 184,999 | Acquired |
| Jan. 5, 2024 | LAB | Stock Option (Right to buy) | Common Stock | $2.08 | March 16, 2033 | 190,365 | Acquired |
| Jan. 5, 2024 | LAB | Stock Option (Right to buy) | Common Stock | $2.60 | Oct. 16, 2032 | 982,811 | Acquired |
| Jan. 5, 2024 | LAB | Stock Option (Right to buy) | Common Stock | $8.18 | Feb. 29, 2032 | 22,866 | Acquired |
| Jan. 5, 2024 | LAB | Stock Option (Right to buy) | Common Stock | $10.68 | Oct. 26, 2031 | 51,842 | Acquired |
| Dec. 7, 2023 | ZYME | Stock Option (Right to Buy) | Common Stock | $9.55 | Dec. 6, 2033 | 37,000 | Acquired |
| Dec. 21, 2022 | ZYME | Stock Option (Right to Buy) | Common Stock | $8.75 | Dec. 20, 2032 | 25,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 4 holdings
Securities held when first becoming an insider, per SEC Form 3.